The fate of low grade dysplasia in ulcerative colitis

Thomas A. Ullman, Edward V. Loftus, Sanjay Kakar, Lawrence J. Burgart, William J. Sandborn, William J. Tremaine

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

OBJECTIVE: The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described. METHODS: We reviewed the Mayo Clinic records of patients with UC found to have flat LGD between 1990 and 1993 in whom a nonoperative strategy was pursued for 2 months or more. RESULTS: Eighteen patients with UC and LGD were observed for a median of 32 months. Nine of 18 patients identified with UC and LGD developed advanced neoplastic lesions during follow-up, which were defined as adenocarcinoma, raised dysplasia, or high grade dysplasia. The cumulative incidence of progression to an advanced lesion was 33% at 5 yr (95% CI = 9-56%). Only one patient developed adenocarcinoma, diagnosed 74 months after his initial finding of LGD and 20 months after his last surveillance exam. Besides this patient, adenocarcinoma was not detected in the colectomy specimens of 13 other patients who underwent surgery. Colectomies were performed for dysplasia or cancer in seven patients, active colitis in five patients, and unknown reasons in two patients. Four patients did not have colectomies. CONCLUSIONS: Neoplastic progression in patients with UC and LGD is common. Total proctocolectomy should be offered to all patients with flat LGD. Our study illustrates numerous pitfalls in the practice of surveillance.

Original languageEnglish (US)
Pages (from-to)922-927
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume97
Issue number4
DOIs
StatePublished - Apr 29 2002
Externally publishedYes

Fingerprint

Ulcerative Colitis
Colectomy
Adenocarcinoma
Colitis
Natural History

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Ullman, T. A., Loftus, E. V., Kakar, S., Burgart, L. J., Sandborn, W. J., & Tremaine, W. J. (2002). The fate of low grade dysplasia in ulcerative colitis. American Journal of Gastroenterology, 97(4), 922-927. https://doi.org/10.1016/S0002-9270(02)03966-7

The fate of low grade dysplasia in ulcerative colitis. / Ullman, Thomas A.; Loftus, Edward V.; Kakar, Sanjay; Burgart, Lawrence J.; Sandborn, William J.; Tremaine, William J.

In: American Journal of Gastroenterology, Vol. 97, No. 4, 29.04.2002, p. 922-927.

Research output: Contribution to journalArticle

Ullman, TA, Loftus, EV, Kakar, S, Burgart, LJ, Sandborn, WJ & Tremaine, WJ 2002, 'The fate of low grade dysplasia in ulcerative colitis', American Journal of Gastroenterology, vol. 97, no. 4, pp. 922-927. https://doi.org/10.1016/S0002-9270(02)03966-7
Ullman, Thomas A. ; Loftus, Edward V. ; Kakar, Sanjay ; Burgart, Lawrence J. ; Sandborn, William J. ; Tremaine, William J. / The fate of low grade dysplasia in ulcerative colitis. In: American Journal of Gastroenterology. 2002 ; Vol. 97, No. 4. pp. 922-927.
@article{b4aeacbbe8c440a682649c27c9668cd7,
title = "The fate of low grade dysplasia in ulcerative colitis",
abstract = "OBJECTIVE: The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described. METHODS: We reviewed the Mayo Clinic records of patients with UC found to have flat LGD between 1990 and 1993 in whom a nonoperative strategy was pursued for 2 months or more. RESULTS: Eighteen patients with UC and LGD were observed for a median of 32 months. Nine of 18 patients identified with UC and LGD developed advanced neoplastic lesions during follow-up, which were defined as adenocarcinoma, raised dysplasia, or high grade dysplasia. The cumulative incidence of progression to an advanced lesion was 33{\%} at 5 yr (95{\%} CI = 9-56{\%}). Only one patient developed adenocarcinoma, diagnosed 74 months after his initial finding of LGD and 20 months after his last surveillance exam. Besides this patient, adenocarcinoma was not detected in the colectomy specimens of 13 other patients who underwent surgery. Colectomies were performed for dysplasia or cancer in seven patients, active colitis in five patients, and unknown reasons in two patients. Four patients did not have colectomies. CONCLUSIONS: Neoplastic progression in patients with UC and LGD is common. Total proctocolectomy should be offered to all patients with flat LGD. Our study illustrates numerous pitfalls in the practice of surveillance.",
author = "Ullman, {Thomas A.} and Loftus, {Edward V.} and Sanjay Kakar and Burgart, {Lawrence J.} and Sandborn, {William J.} and Tremaine, {William J.}",
year = "2002",
month = "4",
day = "29",
doi = "10.1016/S0002-9270(02)03966-7",
language = "English (US)",
volume = "97",
pages = "922--927",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The fate of low grade dysplasia in ulcerative colitis

AU - Ullman, Thomas A.

AU - Loftus, Edward V.

AU - Kakar, Sanjay

AU - Burgart, Lawrence J.

AU - Sandborn, William J.

AU - Tremaine, William J.

PY - 2002/4/29

Y1 - 2002/4/29

N2 - OBJECTIVE: The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described. METHODS: We reviewed the Mayo Clinic records of patients with UC found to have flat LGD between 1990 and 1993 in whom a nonoperative strategy was pursued for 2 months or more. RESULTS: Eighteen patients with UC and LGD were observed for a median of 32 months. Nine of 18 patients identified with UC and LGD developed advanced neoplastic lesions during follow-up, which were defined as adenocarcinoma, raised dysplasia, or high grade dysplasia. The cumulative incidence of progression to an advanced lesion was 33% at 5 yr (95% CI = 9-56%). Only one patient developed adenocarcinoma, diagnosed 74 months after his initial finding of LGD and 20 months after his last surveillance exam. Besides this patient, adenocarcinoma was not detected in the colectomy specimens of 13 other patients who underwent surgery. Colectomies were performed for dysplasia or cancer in seven patients, active colitis in five patients, and unknown reasons in two patients. Four patients did not have colectomies. CONCLUSIONS: Neoplastic progression in patients with UC and LGD is common. Total proctocolectomy should be offered to all patients with flat LGD. Our study illustrates numerous pitfalls in the practice of surveillance.

AB - OBJECTIVE: The optimal strategy for the management of definite low grade dysplasia (LGD) detected in surveillance in ulcerative colitis (UC) is unknown, because the natural history of LGD has not been well described. METHODS: We reviewed the Mayo Clinic records of patients with UC found to have flat LGD between 1990 and 1993 in whom a nonoperative strategy was pursued for 2 months or more. RESULTS: Eighteen patients with UC and LGD were observed for a median of 32 months. Nine of 18 patients identified with UC and LGD developed advanced neoplastic lesions during follow-up, which were defined as adenocarcinoma, raised dysplasia, or high grade dysplasia. The cumulative incidence of progression to an advanced lesion was 33% at 5 yr (95% CI = 9-56%). Only one patient developed adenocarcinoma, diagnosed 74 months after his initial finding of LGD and 20 months after his last surveillance exam. Besides this patient, adenocarcinoma was not detected in the colectomy specimens of 13 other patients who underwent surgery. Colectomies were performed for dysplasia or cancer in seven patients, active colitis in five patients, and unknown reasons in two patients. Four patients did not have colectomies. CONCLUSIONS: Neoplastic progression in patients with UC and LGD is common. Total proctocolectomy should be offered to all patients with flat LGD. Our study illustrates numerous pitfalls in the practice of surveillance.

UR - http://www.scopus.com/inward/record.url?scp=0036121994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036121994&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(02)03966-7

DO - 10.1016/S0002-9270(02)03966-7

M3 - Article

VL - 97

SP - 922

EP - 927

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -